Bentyl Dicycloverine 10 mg 10 capsules

$0.75

Each Bentyle contains 10 mg Dicycloverine, 10 tablets used to treat spasms of the intestines such as occur in irritable bowel syndrome (IBS).

ATC Classification: A03AA07
Active Ingrediant: Dicycloverine
Generic Name: Bentyl
Manufacturer: Sanofi aventis
Strength: 10 Mg
Dosage Type: Capsule
Packaging Type: Foil in Box
Contains: 10 Capsule

Out of stock

Examples of Packages sent

Free worldwide shipping on all orders over $50

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Guaranteed Safe Checkout

Placeholder
Bentyl Dicycloverine 10 mg 10 capsules
$0.75

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Dicycloverine Information

Medication Safety Issues
Sound-alike/look-alike issues:

Dicyclomine may be confused with diphenhydrAMINE, doxycycline, dyclonine

Bentyl may be confused with Aventyl, Benadryl, Bontril, Cantil, Proventil, TRENtal

Geriatric Patients: High-Risk Medication:

Beers Criteria: Dicyclomine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients ≥65 years (independent of diagnosis or condition) due to its highly anticholinergic properties and uncertain effectiveness as an antispasmodic (Beers Criteria [AGS 2019]).

Pharmacy Quality Alliance (PQA): Dicyclomine is identified as a high-risk medication in patients ≥65 years on the PQA’s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans (PQA 2017).

Storage/Stability

Capsule, tablet: Store at room temperature, preferably below 30°C (86°F). Protect tablet from direct sunlight.

Oral solution: Store at 20°C to 25°C (68°F to 77°F); protect from excessive heat.

Solution for injection: Store at room temperature, preferably below 30°C (86°F); protect from freezing.

Adverse Reactions

>10%:

Central nervous system: Dizziness (40%)

Gastrointestinal: Xerostomia (33%), nausea (14%)

Ophthalmic: Blurred vision (27%)

1% to 10%:

Central nervous system: Drowsiness (9%), nervousness (6%)

Neuromuscular & skeletal: Weakness (7%)

Postmarketing and/or case reports: Abdominal distention, abdominal pain, anaphylactic shock, angioedema, confusion, constipation, cycloplegia, decreased lactation, delirium, dermatitis (allergic), dyspepsia, dyspnea, erythema, facial edema, fatigue, hallucination, headache, hypersensitivity, insomnia, malaise, mydriasis, nasal congestion, palpitations, skin rash, syncope, tachyarrhythmia, vomiting –

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type